D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences (ARTL) to Hold from Buy without a price target after the company announced a 6-for-1 reverse stock split set to take effect on June 13. The firm moved to the sidelines “as the company transitions through this corporate action.” The analyst sees limited near-term upside until the shares “find technical and investor support at a new base level.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences announces 6-for-1 reverse stock split
- Artelo Biosciences announces presentation of new data on FABP inhibitors
- Artelo Biosciences announces publication of paper on FABP inhibitor program
- Artelo Biosciences Reports Q1 2025 Financial Results
- Artelo Biosciences Faces Nasdaq Compliance Challenge